112 related articles for article (PubMed ID: 16038734)
61. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Gruber FX; Lamark T; Anonli A; Sovershaev MA; Olsen M; Gedde-Dahl T; Hjort-Hansen H; Skogen B
Leukemia; 2005 Dec; 19(12):2159-65. PubMed ID: 16224487
[TBL] [Abstract][Full Text] [Related]
62. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
Branford S; Cross NC; Hochhaus A; Radich J; Saglio G; Kaeda J; Goldman J; Hughes T
Leukemia; 2006 Nov; 20(11):1925-30. PubMed ID: 16990771
[TBL] [Abstract][Full Text] [Related]
63. [CML with mu-BCR/ABL mRNA: clinical characteristics of our three cases and 26 reported cases].
Ito T
Rinsho Ketsueki; 2003 Apr; 44(4):234-41. PubMed ID: 12784656
[No Abstract] [Full Text] [Related]
64. A nested RT-PCR assay to detect BCR/abl.
Wasserman LM
Methods Mol Med; 2004; 97():181-9. PubMed ID: 15064493
[No Abstract] [Full Text] [Related]
65. Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy.
Sandt C; Feraud O; Bonnet ML; Desterke C; Khedhir R; Flamant S; Bailey CG; Rasko JEJ; Dumas P; Bennaceur-Griscelli A; Turhan AG
Biochem Biophys Res Commun; 2018 Sep; 503(3):1861-1867. PubMed ID: 30057314
[TBL] [Abstract][Full Text] [Related]
66. Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Thomas M; Huang WS; Wen D; Zhu X; Wang Y; Metcalf CA; Liu S; Chen I; Romero J; Zou D; Sundaramoorthi R; Li F; Qi J; Cai L; Zhou T; Commodore L; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Iuliucci J; Rivera VM; Sawyer TK; Dalgarno DC; Clackson T; Shakespeare WC
Bioorg Med Chem Lett; 2011 Jun; 21(12):3743-8. PubMed ID: 21561767
[TBL] [Abstract][Full Text] [Related]
67. [Polymorphism analysis of 5' promotor region of BCR gene].
Tian H; Zheng WY; Fu YG; Lin JH; Lu FJ; Zhou SY
Ai Zheng; 2004 Jul; 23(7):812-5. PubMed ID: 15248918
[TBL] [Abstract][Full Text] [Related]
68. Pharmacologic monitoring and determinants of intracytoplasmic drug levels.
Mahon FX
Best Pract Res Clin Haematol; 2009 Sep; 22(3):381-6. PubMed ID: 19959088
[TBL] [Abstract][Full Text] [Related]
69. Continued therapeutic response monitoring in optimal responders with CML.
Branford S
Clin Adv Hematol Oncol; 2012 Dec; 10(12):819-21. PubMed ID: 23271354
[No Abstract] [Full Text] [Related]
70. Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.
Wang YL; Lee JW; Cesarman E; Jin DK; Csernus B
J Mol Diagn; 2006 May; 8(2):231-9. PubMed ID: 16645210
[TBL] [Abstract][Full Text] [Related]
71. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.
Girerd S; Tosca L; Herault O; Vignon C; Biard D; Aggoune D; Dkhissi F; Bonnet ML; Sorel N; Desterke C; Bennaceur-Griscelli A; Tachdjian G; Guilhot F; Guilhot J; Chomel JC; Turhan AG
Biochem Biophys Res Commun; 2018 Apr; 498(4):715-722. PubMed ID: 29550484
[TBL] [Abstract][Full Text] [Related]
72. Molecular biology to check patients treated for CML.
Saglio G; Zaccaria A; Tassinari A; Rosti G; Lo Coco F; Diverio D; Rege Cambrin G; Scaravaglio P; Rosso C; Guerrasio A
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():98-100. PubMed ID: 2627627
[No Abstract] [Full Text] [Related]
73. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
74. Copper nanoclusters on specific-primer PCR fragments with magnetic capture for the label-free fluorescent sensing of the T315I single nucleotide variant in the
Lai KP; Su YC; Fu BS; Lin KH; Kou HS; Wang CC
Analyst; 2022 Dec; 147(24):5732-5738. PubMed ID: 36394571
[TBL] [Abstract][Full Text] [Related]
75. [Establishment of real-time fluorescent quantitative polymerase chain reaction for rapid detection of M244V mutation in kinase domain of BCR-ABL fusion gene].
Huang Q; DU X; Zhang QX; Zhuo JC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1728-34. PubMed ID: 25543505
[TBL] [Abstract][Full Text] [Related]
76. Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.
Melo JV; Kent NS; Yan XH; Goldman JM
Blood; 1994 Dec; 84(11):3984-6. PubMed ID: 7949158
[No Abstract] [Full Text] [Related]
77. Determination of polymerase chain reaction products by time-resolved immunofluorometry.
Bortolin S; Christopoulos TK
Clin Biochem; 1996 Apr; 29(2):179-82. PubMed ID: 8601329
[No Abstract] [Full Text] [Related]
78. Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients.
Saverno KR; Rochau U; Stenehjem DD; Morley K; Siebert U; Brixner DI
J Manag Care Pharm; 2012; 18(6):457-63. PubMed ID: 22839687
[No Abstract] [Full Text] [Related]
79. Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.
Preuner S; Barna A; Frommlet F; Czurda S; Konstantin B; Alikian M; Machova Polakova K; Sacha T; Richter J; Lion T; Gabriel C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136541
[TBL] [Abstract][Full Text] [Related]
80. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
